News Feed

Diagnosing viruses like Chikungunya usually means relying on lab equipment such as PCR machines, which aren't exactly portable, but researchers at China Pharmaceutical University have developed a simple strip test that skips all that. Their method redesigns the molecular amplification process to create more bridging points for signal detection, then pairs it with gold-platinum nanoparticles that deepen the color readout, making even tiny amounts of virus visible to the naked eye. In testing, the strip matched PCR results with complete accuracy across dozens of samples and held up well in serum, saliva, and urine. Since it needs no fancy instruments, this could be a real game-changer for outbreak surveillance in clinics, ports, and remote field stations where lab access is limited.

For centuries, museums and universities have quietly stored, studied, and displayed human remains, many obtained without consent, like the 19th-century Viennese anatomist Joseph Hyrtl, who built his famous collection by paying grave robbers. The 1990 Native American Graves Protection and Repatriation Act tried to address this by requiring institutions to return remains to descendants or tribes, but progress has been slow and controversies keep surfacing, including the 2021 revelation that the University of Pennsylvania held remains from the 1985 MOVE bombing and used them in anatomy classes. Biological anthropologist Fatimah Jackson is now pushing universities and museums to confront this history and manage remains more ethically. Meanwhile, modern medical schools increasingly rely on voluntary body donation, some even holding ceremonies to honor donors, a stark contrast to Hyrtl's era.

Long COVID fatigue has left many patients with few real treatment options, but a new randomized trial involving 399 adults suggests fluvoxamine, a widely available, inexpensive antidepressant, might actually help. Participants who took the drug saw significantly less fatigue and reported a better quality of life compared to those on a placebo, marking it as one of the first medications to show a meaningful benefit for this exhausting and often dismissed condition. It's an encouraging sign for a disease that has left millions searching for answers, and given how cheap and accessible fluvoxamine already is, it could offer a practical option while researchers keep digging into what's driving long COVID in the first place.

Turns out swapping sugar for artificial sweeteners might come with a hidden cost. A new study found that adults with the highest intake of sugar substitutes experienced noticeably faster declines in memory and thinking, with cognitive aging equivalent to roughly 1.6 years faster compared to those with the lowest intake, and the effect was even more pronounced in people under 60 or living with diabetes. It's a striking association, but researchers are careful to note it doesn't prove sweeteners are the cause, just that more research is needed to sort out what's really going on. Still, it's a good reason to keep an eye on how much diet soda and "sugar-free" everything is sneaking into your daily routine.

Polycystic Kidney Disease (PKD) is an inherited disorder in which fluid-filled cysts gradually develop and enlarge inside the kidneys, potentially damaging healthy tissue over time. The disease can remain silent for years, but warning signs may include high blood pressure at a young age, persistent back or side pain, blood in the urine, recurrent urinary infections, and kidney stones. Early diagnosis through ultrasound and other imaging can help doctors monitor kidney function, control blood pressure, and slow disease progression. Although there is currently no cure, lifestyle changes and treatments such as tolvaptan may help preserve kidney function and delay kidney failure.

Fatty liver disease, now called Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), can affect people who neither drink alcohol nor appear overweight. Doctors warn that the condition is increasingly common among Indians, including young adults and those with sedentary lifestyles. Because it often causes no symptoms in its early stages, liver damage may progress unnoticed from fat accumulation to inflammation, fibrosis, cirrhosis, or even liver cancer. The good news is that early-stage fatty liver can often be improved through weight management, regular exercise, healthier eating, and control of diabetes and cholesterol. An incidental diagnosis should not be ignored—early evaluation can help prevent serious complications.

Researchers at Texas A&M have identified two naturally occurring molecules, microRNA-15a and microRNA-16 - that can significantly slow the growth of non-small cell lung cancer cells. These microRNAs help regulate protein production and restore normal cellular balance, reducing the uncontrolled growth that drives cancer. While the discovery is not a cure, scientists believe it could become part of future combination therapies alongside surgery, radiation, or targeted drugs. The team is now exploring ways to deliver these microRNAs directly to tumor cells using engineered viral systems. This promising approach may one day help slow lung cancer progression and improve patient survival.

A new study published in JAMA Network Open suggests that a single application of 1% chlorhexidine, a low-cost antiseptic, during labor and shortly after birth could significantly reduce harmful bacteria linked to neonatal sepsis. In a clinical trial involving mothers and newborns in Malawi, the treatment lowered bacterial levels by nearly 3,000-fold in mothers and 16-fold in babies without causing serious side effects. Researchers found that a higher 2% concentration offered no added benefit. Because chlorhexidine is inexpensive and widely available, it could become an effective, scalable strategy to help prevent life-threatening newborn infections, especially in low- and middle-income countries.

A new study published in the Annals of Internal Medicine found that adding GLP-1 receptor agonists (GLP-1 RAs) to basal insulin therapy does not increase the likelihood of stopping insulin in people with type 2 diabetes compared with SGLT2 inhibitors or DPP-4 inhibitors. Researchers analyzed data from more than 8,800 matched groups of U.S. veterans with type 2 diabetes and observed similar insulin discontinuation rates across all three treatment options over three years. While GLP-1 RAs continue to provide important heart, kidney, and weight-loss benefits, the findings suggest they do not offer a unique advantage in helping patients discontinue basal insulin therapy.

Scientists at Northwestern Medicine have discovered that the immune receptor A2A plays a surprising dual role in cancer. Instead of acting only as an immune "brake," both excessive A2A activity and its complete loss can push cancer-fighting CD8+ T cells into an exhausted, ineffective state through different biological pathways. Using advanced single-cell analysis, researchers identified CD122 signaling as a key driver of this process when A2A is absent. The findings help explain why A2A-targeted cancer therapies have shown limited success in clinical trials and suggest that future treatments should carefully fine-tune immune signaling rather than simply blocking it, potentially leading to more effective cancer immunotherapies.